145 related articles for article (PubMed ID: 21113744)
1. Establishment of three cisplatin-resistant endometrial cancer cell lines using two methods of cisplatin exposure.
Sagawa Y; Fujitoh A; Nishi H; Ito H; Yudate T; Isaka K
Tumour Biol; 2011 Apr; 32(2):399-408. PubMed ID: 21113744
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
3. Anti-cancer effects of newly developed chemotherapeutic agent, glycoconjugated palladium (II) complex, against cisplatin-resistant gastric cancer cells.
Tanaka M; Kataoka H; Yano S; Ohi H; Kawamoto K; Shibahara T; Mizoshita T; Mori Y; Tanida S; Kamiya T; Joh T
BMC Cancer; 2013 May; 13():237. PubMed ID: 23672493
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
Mizutani Y; Fukumoto M; Bonavida B; Yoshida O
Cancer; 1994 Nov; 74(9):2546-54. PubMed ID: 7923012
[TBL] [Abstract][Full Text] [Related]
5. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
Daga M; Pizzimenti S; Dianzani C; Cucci MA; Cavalli R; Grattarola M; Ferrara B; Scariot V; Trotta F; Barrera G
Phytomedicine; 2019 Mar; 56():156-164. PubMed ID: 30668336
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of stepwise and pulse induced cisplatin-resistant ovarian cancer cell sublines].
Cheng G; Li Y; Tian F
Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):305-8. PubMed ID: 11783113
[TBL] [Abstract][Full Text] [Related]
7. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
8. Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line.
Wen J; Zheng B; Hu Y; Zhang X; Yang H; Luo KJ; Zhang X; Li YF; Fu JH
Oncol Rep; 2009 Jul; 22(1):65-71. PubMed ID: 19513506
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
10. Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer.
Noma B; Sasaki T; Fujimoto Y; Serikawa M; Kobayashi K; Inoue M; Itsuki H; Kamigaki M; Minami T; Chayama K
Int J Oncol; 2008 Dec; 33(6):1187-94. PubMed ID: 19020751
[TBL] [Abstract][Full Text] [Related]
11. Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
Minagawa Y; Kigawa J; Irie T; Kanamori Y; Itamochi H; Cheng X; Terakawa N
Jpn J Cancer Res; 1997 Dec; 88(12):1218-23. PubMed ID: 9473741
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line.
Kishimoto S; Miyazawa K; Terakawa Y; Ashikari H; Ohtani A; Fukushima S; Takeuchi Y
Jpn J Cancer Res; 2000 Dec; 91(12):1326-32. PubMed ID: 11123433
[TBL] [Abstract][Full Text] [Related]
13. Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines.
Gentilin E; Minoia M; Bondanelli M; Tagliati F; Degli Uberti EC; Zatelli MC
Endocrine; 2017 Jun; 56(3):621-632. PubMed ID: 27585662
[TBL] [Abstract][Full Text] [Related]
14. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves.
Nishiyama M; Yamamoto W; Park JS; Okamoto R; Hanaoka H; Takano H; Saito N; Matsukawa M; Shirasaka T; Kurihara M
Clin Cancer Res; 1999 Sep; 5(9):2620-8. PubMed ID: 10499641
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines.
Hong WS; Saijo N; Sasaki Y; Minato K; Nakano H; Nakagawa K; Fujiwara Y; Nomura K; Twentyman PR
Int J Cancer; 1988 Mar; 41(3):462-7. PubMed ID: 3346112
[TBL] [Abstract][Full Text] [Related]
16. Steroid and xenobiotic receptor (SXR) is a key system for the acquisition of cisplatin resistance in endometrial cancer cells.
Takami N; Sakamoto H; Yamamoto T
J Int Med Res; 2003; 31(2):59-68. PubMed ID: 12760308
[TBL] [Abstract][Full Text] [Related]
17. Emodin Enhances the Chemosensitivity of Endometrial Cancer by Inhibiting ROS-Mediated Cisplatin-resistance.
Ding N; Zhang H; Su S; Ding Y; Yu X; Tang Y; Wang Q; Liu P
Anticancer Agents Med Chem; 2018; 18(7):1054-1063. PubMed ID: 29256357
[TBL] [Abstract][Full Text] [Related]
18. A novel mechanism for acquired cisplatin-resistance: suppressed translation of death-associated protein kinase mRNA is insensitive to 5-aza-2'-deoxycitidine and trichostatin in cisplatin-resistant cervical squamous cancer cells.
Bai T; Tanaka T; Yukawa K; Umesaki N
Int J Oncol; 2006 Feb; 28(2):497-508. PubMed ID: 16391806
[TBL] [Abstract][Full Text] [Related]
19. Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines.
Smith JA; Gaikwad A; Ramondetta LM; Wolf JK; Brown J
Gynecol Oncol; 2006 Nov; 103(2):518-22. PubMed ID: 16690105
[TBL] [Abstract][Full Text] [Related]
20. Intracellular uptake of an antitumor-active azole-bridged dinuclear platinum(II) complex in cisplatin-resistant tumor cells.
Kishimoto S; Yasuda M; Suzuki R; Fukushima S
Biometals; 2016 Dec; 29(6):1075-1083. PubMed ID: 27787693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
